Karyopharm Historical Balance Sheet

KPTI Stock

USD 0.73 0.04 5.19%

Trend analysis of Karyopharm Therapeutics balance sheet accounts such as Property Plant And Equipment Net of 3 M provides information on Karyopharm Therapeutics' total assets, liabilities, and equity, which is the actual value of Karyopharm Therapeutics to its prevalent stockholders. By breaking down trends over time using Karyopharm Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Karyopharm Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Karyopharm Therapeutics is a good buy for the upcoming year.

Karyopharm Therapeutics Inventory

1.58 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

About Karyopharm Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Karyopharm Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Karyopharm Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Karyopharm Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Karyopharm currently owns. An asset can also be divided into two categories, current and non-current.

Karyopharm Therapeutics Balance Sheet Chart

As of now, Karyopharm Therapeutics' Accounts Payable is increasing as compared to previous years. The Karyopharm Therapeutics' current Cash is estimated to increase to about 101.6 M, while Total Assets are projected to decrease to under 238.3 M.

Total Assets Total Current Liabilities Property Plant And Equipment Net Preferred Stock Total Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Karyopharm Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Karyopharm Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Karyopharm Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Karyopharm Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Karyopharm Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.As of now, Karyopharm Therapeutics' Accounts Payable is increasing as compared to previous years. The Karyopharm Therapeutics' current Cash is estimated to increase to about 101.6 M, while Total Assets are projected to decrease to under 238.3 M.

	2021	2022	2023	2024 (projected)
Cash	190.5M	135.2M	52.2M	101.6M
Accounts Payable	1.6M	2.8M	3.1M	3.5M

Cash Accounts Payable

Karyopharm Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.5	0.63	0.09	0.74	0.44	0.16	-0.74	0.39	0.74	0.48	0.44	0.37	0.98	0.74	0.66	0.57	0.88	0.67	0.48	0.99	0.33	0.63	-0.5	0.57	-0.78
Other Current Liab	0.5		0.86	-0.66	0.54	0.64	0.57	-0.81	-0.2	0.43	0.27	0.68	0.21	0.39	0.78	0.84	0.86	0.67	0.86	0.41	0.47	-0.21	0.03	-0.87	0.84	-0.78
Total Current Liabilities	0.63	0.86		-0.47	0.63	0.65	0.52	-0.83	0.07	0.46	0.29	0.58	0.14	0.55	0.83	0.75	0.83	0.75	0.82	0.38	0.61	0.14	0.25	-0.76	0.83	-0.81
Total Stockholder Equity	0.09	-0.66	-0.47		-0.05	-0.21	-0.81	0.57	0.53	0.16	0.22	-0.34	-0.23	0.17	-0.48	-0.67	-0.54	-0.29	-0.68	-0.31	0.08	0.66	0.52	0.77	-0.66	0.53
Property Plant And Equipment Net	0.74	0.54	0.63	-0.05		0.33	0.38	-0.67	0.36	0.31	0.36	0.24	-0.13	0.68	0.68	0.55	0.6	0.77	0.58	0.33	0.73	0.34	0.44	-0.39	0.67	-0.68
Current Deferred Revenue	0.44	0.64	0.65	-0.21	0.33		0.07	-0.47	0.18	0.49	0.66	0.74	0.52	0.32	0.46	0.47	0.73	0.5	0.47	-0.08	0.37	0.21	0.2	-0.54	0.36	-0.48
Net Debt	0.16	0.57	0.52	-0.81	0.38	0.07		-0.72	-0.2	-0.28	-0.13	0.07	0.07	0.1	0.69	0.68	0.47	0.49	0.73	0.56	0.18	-0.28	-0.08	-0.65	0.8	-0.67
Retained Earnings	-0.74	-0.81	-0.83	0.57	-0.67	-0.47	-0.72		-0.09	-0.41	-0.27	-0.46	-0.36	-0.67	-0.97	-0.94	-0.77	-0.92	-0.97	-0.66	-0.74	0.09	-0.22	0.88	-0.94	0.99
Accounts Payable	0.39	-0.2	0.07	0.53	0.36	0.18	-0.2	-0.09		0.17	0.33	-0.33	-0.05	0.4	0.25	-0.18	-0.08	0.22	-0.1	0.11	0.36	0.78	0.63	0.25	0.03	-0.07
Cash	0.74	0.43	0.46	0.16	0.31	0.49	-0.28	-0.41	0.17		0.31	0.6	0.41	0.75	0.38	0.46	0.51	0.5	0.43	0.13	0.74	0.13	0.31	-0.39	0.27	-0.45
Non Current Assets Total	0.48	0.27	0.29	0.22	0.36	0.66	-0.13	-0.27	0.33	0.31		0.51	0.44	0.36	0.25	0.21	0.31	0.43	0.18	-0.02	0.36	0.33	0.47	-0.25	0.07	-0.34
Non Currrent Assets Other	0.44	0.68	0.58	-0.34	0.24	0.74	0.07	-0.46	-0.33	0.6	0.51		0.58	0.34	0.32	0.64	0.74	0.48	0.57	-0.07	0.4	-0.22	-0.02	-0.68	0.31	-0.53
Other Assets	0.37	0.21	0.14	-0.23	-0.13	0.52	0.07	-0.36	-0.05	0.41	0.44	0.58		0.31	0.25	0.5	0.34	0.41	0.43	0.11	0.33	-0.24	0.03	-0.52	0.11	-0.43
Cash And Short Term Investments	0.98	0.39	0.55	0.17	0.68	0.32	0.1	-0.67	0.4	0.75	0.36	0.34	0.31		0.68	0.59	0.46	0.81	0.6	0.5	0.99	0.36	0.66	-0.39	0.5	-0.7
Common Stock Shares Outstanding	0.74	0.78	0.83	-0.48	0.68	0.46	0.69	-0.97	0.25	0.38	0.25	0.32	0.25	0.68		0.84	0.7	0.87	0.9	0.72	0.73	0.08	0.36	-0.78	0.94	-0.93
Non Current Liabilities Total	0.66	0.84	0.75	-0.67	0.55	0.47	0.68	-0.94	-0.18	0.46	0.21	0.64	0.5	0.59	0.84		0.82	0.84	0.99	0.55	0.66	-0.32	0.04	-0.95	0.86	-0.95
Other Current Assets	0.57	0.86	0.83	-0.54	0.6	0.73	0.47	-0.77	-0.08	0.51	0.31	0.74	0.34	0.46	0.7	0.82		0.69	0.82	0.08	0.55	-0.07	-0.04	-0.81	0.77	-0.78
Other Stockholder Equity	0.88	0.67	0.75	-0.29	0.77	0.5	0.49	-0.92	0.22	0.5	0.43	0.48	0.41	0.81	0.87	0.84	0.69		0.86	0.58	0.87	0.07	0.37	-0.75	0.79	-0.95
Total Liab	0.67	0.86	0.82	-0.68	0.58	0.47	0.73	-0.97	-0.1	0.43	0.18	0.57	0.43	0.6	0.9	0.99	0.82	0.86		0.59	0.67	-0.24	0.09	-0.94	0.92	-0.97
Property Plant And Equipment Gross	0.48	0.41	0.38	-0.31	0.33	-0.08	0.56	-0.66	0.11	0.13	-0.02	-0.07	0.11	0.5	0.72	0.55	0.08	0.58	0.59		0.5	-0.1	0.41	-0.46	0.62	-0.61
Total Current Assets	0.99	0.47	0.61	0.08	0.73	0.37	0.18	-0.74	0.36	0.74	0.36	0.4	0.33	0.99	0.73	0.66	0.55	0.87	0.67	0.5		0.3	0.59	-0.48	0.58	-0.77
Short Term Debt	0.33	-0.21	0.14	0.66	0.34	0.21	-0.28	0.09	0.78	0.13	0.33	-0.22	-0.24	0.36	0.08	-0.32	-0.07	0.07	-0.24	-0.1	0.3		0.77	0.44	-0.13	0.1
Property Plant Equipment	0.63	0.03	0.25	0.52	0.44	0.2	-0.08	-0.22	0.63	0.31	0.47	-0.02	0.03	0.66	0.36	0.04	-0.04	0.37	0.09	0.41	0.59	0.77		0.14	0.09	-0.23
Net Tangible Assets	-0.5	-0.87	-0.76	0.77	-0.39	-0.54	-0.65	0.88	0.25	-0.39	-0.25	-0.68	-0.52	-0.39	-0.78	-0.95	-0.81	-0.75	-0.94	-0.46	-0.48	0.44	0.14		-0.83	0.89
Common Stock Total Equity	0.57	0.84	0.83	-0.66	0.67	0.36	0.8	-0.94	0.03	0.27	0.07	0.31	0.11	0.5	0.94	0.86	0.77	0.79	0.92	0.62	0.58	-0.13	0.09	-0.83		-0.89
Retained Earnings Total Equity	-0.78	-0.78	-0.81	0.53	-0.68	-0.48	-0.67	0.99	-0.07	-0.45	-0.34	-0.53	-0.43	-0.7	-0.93	-0.95	-0.78	-0.95	-0.97	-0.61	-0.77	0.1	-0.23	0.89	-0.89

Click cells to compare fundamentals

Karyopharm Therapeutics Account Relationship Matchups

Karyopharm Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	295.0M	313.1M	305.3M	358.2M	240.4M	238.3M
Other Current Liab	41.4M	(6.4M)	67.5M	57.4M	59.7M	62.7M
Total Current Liabilities	46.4M	297K	73.7M	65.9M	69.5M	73.0M
Total Stockholder Equity	49.8M	50.5M	(79.7M)	(16.7M)	(136.2M)	(129.4M)
Property Plant And Equipment Net	3.0M	2.2M	1.6M	7.4M	4.9M	3.0M
Current Deferred Revenue	2.3M	297K	69.1M	25.1M	28.8M	15.7M
Net Debt	(19.0M)	32.0M	(21.2M)	37.8M	124.8M	131.0M
Retained Earnings	(873.3M)	(1.1B)	(1.2B)	(1.3B)	(1.5B)	(1.4B)
Accounts Payable	985K	4.5M	1.6M	2.8M	3.1M	3.5M
Cash	128.9M	85.9M	190.5M	135.2M	52.2M	101.6M
Non Current Assets Total	21.3M	23.5M	47.2M	31.4M	6.5M	6.2M
Non Currrent Assets Other	16.2M	(2.9M)	44.9M	23.4M	1.6M	1.6M
Other Assets	714K	34.3M	45.6M	633K	1.0	0.95
Cash And Short Term Investments	264.0M	273.5M	228.6M	278.0M	191.4M	201.7M
Common Stock Shares Outstanding	62.0M	72.0M	75.2M	81.9M	114.2M	119.9M
Liabilities And Stockholders Equity	295.0M	313.1M	305.3M	358.2M	240.4M	238.3M
Non Current Liabilities Total	245.2M	262.2M	385.0M	374.8M	307.2M	322.5M
Other Current Assets	1.5M	559K	20.4M	20.9M	12.5M	13.1M
Other Stockholder Equity	923.1M	1.1B	1.1B	1.3B	1.4B	748.9M
Total Liab	245.2M	262.5M	385.0M	374.8M	376.6M	395.5M
Property Plant And Equipment Gross	13.7M	11.6M	1.6M	1.1M	11.4M	12.0M
Total Current Assets	273.7M	289.5M	258.1M	326.8M	233.9M	215.6M
Accumulated Other Comprehensive Income	(37K)	518K	191K	(638K)	(161K)	(169.1K)
Short Term Debt	1.6M	1.9M	4.6M	5.7M	6.6M	8.5M
Property Plant Equipment	3.0M	2.2M	1.6M	1.1M	1.3M	2.2M
Net Tangible Assets	49.8M	50.5M	(79.7M)	(16.7M)	(15.0M)	(14.2M)
Long Term Debt	109.9M	117.9M	169.3M	170.1M	170.9M	179.5M
Retained Earnings Total Equity	(873.3M)	(1.1B)	(1.2B)	(1.3B)	(1.2B)	(1.1B)
Short Term Investments	133.1M	163.3M	38.2M	142.8M	139.2M	115.6M
Capital Surpluse	923.1M	1.1B	1.1B	1.3B	1.5B	824.8M
Other Liab	8.5M	75.8M	144.6M	215.7M	248.0M	260.4M
Net Invested Capital	159.6M	168.5M	169.3M	170.1M	34.7M	33.0M
Net Working Capital	232.2M	216.3M	201.9M	284.3M	164.4M	233.5M
Short Long Term Debt Total	111.5M	119.8M	169.3M	173.0M	177.0M	162.5M

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:

How To Invest In Karyopharm

Details

Is Karyopharm Stock a good investment?

Details

What is Karyopharm Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.05)

Revenue Per Share

1.247

Quarterly Revenue Growth

0.077

Return On Assets

(0.34)

Return On Equity

(8.91)

The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Karyopharm Historical Balance Sheet

Karyopharm Therapeutics Inventory

1.58 Million

About Karyopharm Balance Sheet Analysis

Karyopharm Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Karyopharm Therapeutics balance sheet Correlations

Karyopharm Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Karyopharm Therapeutics balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Retained Earnings Total Equity	+ 0.99	Retained Earnings
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets
Common Stock Total Equity	+ 0.94	Common Stock Shares Outstanding

Retained Earnings Total Equity	- 0.97	Total Liab
Total Liab	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings Total Equity	- 0.95	Other Stockholder Equity
Retained Earnings Total Equity	- 0.95	Non Current Liabilities Total
Net Tangible Assets	- 0.95	Non Current Liabilities Total